Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy

Acquired drug resistance decreases the efficacy of gefitinib after approximately 1 year of treatment in non-small-cell lung cancer (NSCLC). Autophagy is a process that could lead to cell death when it is prolonged. Thus, we investigated a drug combination therapy of gefitinib with rapamycin—a cell a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuhong, Dai, Xiaoyong, Jiang, Shengwei, Qahar, Mulan, Feng, Chunyan, Guo, Dongdong, Wang, Lijun, Ma, Shaohua, Huang, Laiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316473/
https://www.ncbi.nlm.nih.gov/pubmed/35887373
http://dx.doi.org/10.3390/ijms23148025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316473/
https://www.ncbi.nlm.nih.gov/pubmed/35887373
http://dx.doi.org/10.3390/ijms23148025

Ejemplares similares